One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome. The liposome may comprise at least one lipid, and may further comprise at least one active platinum compound. The disclosure also relates to a pharmaceutical formulation comprising a lipid complexed active platinum compound and a pharmaceutically acceptable carrier or diluent. The pharmaceutical formulation may be formulated for inhalation or injection.Selon un aspect, la présente invention concerne une nouvelle forme de composé de platine actif à complexe lipidique, qui assure des concentrations élevées de composé de platine dans la composition. Par exemple, la concentration de cisplatine dans la composition est supérieure à la température ambiante, par exemple, supérieure à 1,2 mg/mL comparée à 1 mg/mL en solution aqueuse. Selon un mode de réalisation, la présente invention concerne une composition comportant un composé de platine à complexe lipidique, le complexe comprenant un rapport lipide/médicament (L/D) inférieur à environ 1 en poids, par exemple entre 0,01 et 1. Le composé de platine actif à complexe lipide comporte au moins un lipide et au moins un compo
